





PTO/SB/08b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

**Complete if Known**

Application Number	
Filing Date	
First Named Inventor	
Group Art Unit	
Examiner Name	
Attorney Docket Number	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
PL		BONVINI et al, "Nuclear $\beta$ -Catenin Displays GSK-3 $\beta$ - and APC-Independent Proteasome Sensitivity in Melanoma Cells", <u>Biochimica et Biophysica Acta</u> 1495:308-318 (2000)	
		FANG et al, "Phosphorylation and Inactivation of Glycogen Synthase Kinase 3 by Protein Kinase A", <u>Proc Natl Acad Sci</u> 97(22):11960-11965 (2000)	
		FERKLEY et al, "GSK-3: New Thoughts on an Old Enzyme", <u>Developmental Biology</u> 225:471-479 (2000)	
		FISHMAN et al, "Evidence for Involvement of Wnt Signaling Pathway in IB-MECA Mediated Suppression of Melanoma Cells", <u>Oncogene</u> 21:4060-4064 (2002)	
		OLAH et al, "The Role of Receptor Structure in Determining Adenosine Receptor Activity", <u>Pharmacology &amp; Therapeutics</u> 85:55-75 (2000)	
		POULSEN et al, "Adenosine Receptors: New Opportunities for Future Drugs", <u>Bioorganic &amp; Medicinal Chemistry</u> 6:619-641 (1998)	
PL		SZABÓ et al, "Suppression of Macrophage Inflammatory Protein (MIP)-1 $\alpha$ Production and Collagen-Induced Arthritis by Adenosine Receptor Agonists", <u>British Journal of Pharmacology</u> 125:379-387 (1998)	

Examiner  
SignatureDate  
Considered

4-4-05

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/715,823
		Filing Date	11-19-2003
		First Named Inventor	Pnina FISHMAN
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	FISHMAN=11A
Sheet 1	of 2		

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	4-4-05
-----------------------	--------------------	--------------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/715,823
		Filing Date	11-19-2003
		First Named Inventor	Pnina FISHMAN
		Group Art Unit	
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	FISHMAN=11A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
PC	BB	BAHARAV, Ehud, et al, "The Anti-Inflammatory Effect of A3 Adenosine Receptor Agonists in Murine Autoimmune Arthritis Models", International Journal of Molecular Medicine, v. 12, n. Supplement 1, pp. S42 (2003).	
	BC	BAHARAV, Ehud, et al, "The Effect of Adenosine and the A3 Adenosine Receptor Agonist IB-MECA on Joint Inflammation and Autoimmune Diseases Models", International Journal of Molecular Medicine, v. 10, n. Supplement 1, pp. S104 (2002).	
	BD	FANG, G., et al, "Adenosine (ADO) Agonists Protect Mice from Death in a Model of Endotoxemia by Binding to A <sub>2A</sub> but not A <sub>3</sub> ADO Receptors", Abstracts of the Interscience Conference on AntiMicrobial Agents and Chemotherapy, v. 41, pp. 754, (2001).	
	BE	HASKO, G., et al, "Stimulation of Adenosine 3 Receptors Exerts Anti-Inflammatory Effects in Acute and Chronic Models of Inflammation", Drug Development Research, v. 43, n.1, pp. 39, (January 1998).	
	BF	MABLEY, Jon, et al, "The A3 Adenosine Agonist, IB-MECA, Protects Against the Development of Arthritis and Reverses Established Arthritis", FASEB Journal, vol. 16, n. 5, pp. A1044, (22 March 2002).	
PC	BG	SZABO, Csaba, et al, "Suppression of Macrophage Inflammatory Protein (MIP)-1 $\alpha$ Production and Collagen-Induced Arthritis by Adenosine Receptor Agonists", British Journal of Pharmacology, v. 125, pp.379-387, (1998).	

Examiner Signature		Date Considered	4-4-05
--------------------	---	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.